|
Gene: BCOR |
Gene summary for BCOR |
Gene summary. |
Gene information | Species | Human | Gene symbol | BCOR | Gene ID | 54880 |
Gene name | BCL6 corepressor | |
Gene Alias | ANOP2 | |
Cytomap | Xp11.4 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q6W2J9 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
54880 | BCOR | HTA11_347_2000001011 | Human | Colorectum | AD | 8.61e-03 | 1.04e-01 | -0.1954 |
54880 | BCOR | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.75e-02 | 1.74e-01 | 0.281 |
54880 | BCOR | A002-C-116 | Human | Colorectum | FAP | 3.14e-03 | 1.71e-01 | -0.0452 |
54880 | BCOR | NAFLD1 | Human | Liver | NAFLD | 3.58e-05 | 3.78e-01 | -0.04 |
54880 | BCOR | HCC1_Meng | Human | Liver | HCC | 5.65e-20 | -4.97e-03 | 0.0246 |
54880 | BCOR | HCC2_Meng | Human | Liver | HCC | 6.28e-09 | 3.83e-02 | 0.0107 |
54880 | BCOR | HCC2 | Human | Liver | HCC | 2.22e-02 | 1.94e+00 | 0.5341 |
54880 | BCOR | S014 | Human | Liver | HCC | 1.61e-08 | 3.92e-01 | 0.2254 |
54880 | BCOR | S015 | Human | Liver | HCC | 1.72e-04 | 2.59e-01 | 0.2375 |
54880 | BCOR | S016 | Human | Liver | HCC | 7.10e-11 | 3.24e-01 | 0.2243 |
54880 | BCOR | S027 | Human | Liver | HCC | 8.76e-06 | 3.95e-01 | 0.2446 |
54880 | BCOR | S028 | Human | Liver | HCC | 5.34e-06 | 3.97e-01 | 0.2503 |
54880 | BCOR | S029 | Human | Liver | HCC | 2.25e-12 | 5.53e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0001701 | Colorectum | AD | in utero embryonic development | 110/3918 | 367/18723 | 2.36e-05 | 4.62e-04 | 110 |
GO:0033522 | Colorectum | AD | histone H2A ubiquitination | 12/3918 | 26/18723 | 3.47e-03 | 2.51e-02 | 12 |
GO:0010452 | Colorectum | AD | histone H3-K36 methylation | 8/3918 | 15/18723 | 5.67e-03 | 3.64e-02 | 8 |
GO:0031056 | Colorectum | AD | regulation of histone modification | 45/3918 | 152/18723 | 7.05e-03 | 4.31e-02 | 45 |
GO:0006513 | Colorectum | AD | protein monoubiquitination | 23/3918 | 67/18723 | 7.55e-03 | 4.58e-02 | 23 |
GO:0001503 | Colorectum | AD | ossification | 106/3918 | 408/18723 | 7.68e-03 | 4.64e-02 | 106 |
GO:00017012 | Colorectum | MSS | in utero embryonic development | 99/3467 | 367/18723 | 3.71e-05 | 7.10e-04 | 99 |
GO:0016570 | Colorectum | MSS | histone modification | 113/3467 | 463/18723 | 8.37e-04 | 8.68e-03 | 113 |
GO:00335221 | Colorectum | MSS | histone H2A ubiquitination | 12/3467 | 26/18723 | 1.16e-03 | 1.12e-02 | 12 |
GO:00015032 | Colorectum | MSS | ossification | 96/3467 | 408/18723 | 6.09e-03 | 4.07e-02 | 96 |
GO:00310562 | Colorectum | MSS | regulation of histone modification | 41/3467 | 152/18723 | 6.41e-03 | 4.27e-02 | 41 |
GO:00065131 | Colorectum | MSS | protein monoubiquitination | 21/3467 | 67/18723 | 7.90e-03 | 4.84e-02 | 21 |
GO:0016574 | Colorectum | MSS | histone ubiquitination | 16/3467 | 47/18723 | 8.22e-03 | 4.99e-02 | 16 |
GO:00017013 | Colorectum | FAP | in utero embryonic development | 81/2622 | 367/18723 | 1.58e-05 | 4.10e-04 | 81 |
GO:00165701 | Colorectum | FAP | histone modification | 94/2622 | 463/18723 | 1.06e-04 | 1.76e-03 | 94 |
GO:00104521 | Colorectum | FAP | histone H3-K36 methylation | 8/2622 | 15/18723 | 3.75e-04 | 4.63e-03 | 8 |
GO:00015033 | Colorectum | FAP | ossification | 79/2622 | 408/18723 | 1.53e-03 | 1.37e-02 | 79 |
GO:00335222 | Colorectum | FAP | histone H2A ubiquitination | 10/2622 | 26/18723 | 1.77e-03 | 1.53e-02 | 10 |
GO:0006479 | Colorectum | FAP | protein methylation | 39/2622 | 181/18723 | 3.60e-03 | 2.58e-02 | 39 |
GO:0008213 | Colorectum | FAP | protein alkylation | 39/2622 | 181/18723 | 3.60e-03 | 2.58e-02 | 39 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BCOR | SNV | Missense_Mutation | novel | c.1910N>T | p.Ser637Phe | p.S637F | Q6W2J9 | protein_coding | deleterious(0.04) | possibly_damaging(0.851) | TCGA-DS-A5RQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
BCOR | SNV | Missense_Mutation | novel | c.3626G>A | p.Arg1209His | p.R1209H | Q6W2J9 | protein_coding | tolerated(0.11) | probably_damaging(0.996) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
BCOR | SNV | Missense_Mutation | rs199538037 | c.4376N>G | p.Asn1459Ser | p.N1459S | Q6W2J9 | protein_coding | deleterious(0) | possibly_damaging(0.578) | TCGA-EA-A4BA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
BCOR | SNV | Missense_Mutation | c.366N>A | p.Met122Ile | p.M122I | Q6W2J9 | protein_coding | tolerated(0.54) | benign(0) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
BCOR | SNV | Missense_Mutation | rs199538037 | c.4376N>G | p.Asn1459Ser | p.N1459S | Q6W2J9 | protein_coding | deleterious(0) | possibly_damaging(0.578) | TCGA-JW-A5VH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
BCOR | SNV | Missense_Mutation | novel | c.1132A>G | p.Thr378Ala | p.T378A | Q6W2J9 | protein_coding | tolerated(0.18) | benign(0.08) | TCGA-JW-AAVH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
BCOR | SNV | Missense_Mutation | c.8N>T | p.Ser3Leu | p.S3L | Q6W2J9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.989) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
BCOR | SNV | Missense_Mutation | novel | c.5030N>T | p.Ser1677Phe | p.S1677F | Q6W2J9 | protein_coding | deleterious(0) | possibly_damaging(0.851) | TCGA-MA-AA3Y-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
BCOR | SNV | Missense_Mutation | novel | c.413N>T | p.Ser138Phe | p.S138F | Q6W2J9 | protein_coding | deleterious(0.01) | possibly_damaging(0.794) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
BCOR | SNV | Missense_Mutation | novel | c.3421G>A | p.Asp1141Asn | p.D1141N | Q6W2J9 | protein_coding | tolerated(0.06) | probably_damaging(0.995) | TCGA-VS-A9U7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
54880 | BCOR | CLINICALLY ACTIONABLE | N/A | 26150234,26098867,26573325,26516930 | ||
54880 | BCOR | CLINICALLY ACTIONABLE | Tretinoin | TRETINOIN | 25790901 |
Page: 1 |